• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

重组无序的无定形药物制剂科学的必要性。

The Need for Restructuring the Disordered Science of Amorphous Drug Formulations.

作者信息

Edueng Khadijah, Mahlin Denny, Bergström Christel A S

机构信息

Department of Pharmacy, Uppsala University, Uppsala Biomedical Centre, P.O. Box 580, SE-75123, Uppsala, Sweden.

Kulliyyah of Pharmacy,, International Islamic University Malaysia, Jalan Istana, 25200, Bandar Indera Mahkota, Pahang, Malaysia.

出版信息

Pharm Res. 2017 Sep;34(9):1754-1772. doi: 10.1007/s11095-017-2174-7. Epub 2017 May 18.

DOI:10.1007/s11095-017-2174-7
PMID:28523384
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5533858/
Abstract

The alarming numbers of poorly soluble discovery compounds have centered the efforts towards finding strategies to improve the solubility. One of the attractive approaches to enhance solubility is via amorphization despite the stability issue associated with it. Although the number of amorphous-based research reports has increased tremendously after year 2000, little is known on the current research practice in designing amorphous formulation and how it has changed after the concept of solid dispersion was first introduced decades ago. In this review we try to answer the following questions: What model compounds and excipients have been used in amorphous-based research? How were these two components selected and prepared? What methods have been used to assess the performance of amorphous formulation? What methodology have evolved and/or been standardized since amorphous-based formulation was first introduced and to what extent have we embraced on new methods? Is the extent of research mirrored in the number of marketed amorphous drug products? We have summarized the history and evolution of amorphous formulation and discuss the current status of amorphous formulation-related research practice. We also explore the potential uses of old experimental methods and how they can be used in tandem with computational tools in designing amorphous formulation more efficiently than the traditional trial-and-error approach.

摘要

难溶性发现化合物数量惊人,这使得人们将精力集中在寻找提高溶解度的策略上。尽管存在与之相关的稳定性问题,但增强溶解度的一种有吸引力的方法是通过非晶化。尽管2000年之后基于非晶态的研究报告数量大幅增加,但对于当前设计非晶体制剂的研究实践以及几十年前首次引入固体分散体概念后其如何变化,人们知之甚少。在本综述中,我们试图回答以下问题:在基于非晶态的研究中使用了哪些模型化合物和辅料?这两种成分是如何选择和制备的?使用了哪些方法来评估非晶体制剂的性能?自从首次引入基于非晶态的制剂以来,哪些方法已经发展和/或标准化,以及我们在何种程度上采用了新方法?研究的程度是否反映在上市的非晶态药品数量上?我们总结了非晶体制剂的历史和演变,并讨论了与非晶体制剂相关的研究实践的现状。我们还探讨了旧实验方法的潜在用途,以及它们如何与计算工具协同使用,以比传统的试错方法更有效地设计非晶体制剂。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f303/5533858/4dbdf511a870/11095_2017_2174_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f303/5533858/30fff98cabb5/11095_2017_2174_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f303/5533858/86c22b1c39fd/11095_2017_2174_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f303/5533858/b4fcdfa59d2d/11095_2017_2174_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f303/5533858/77040df1e6e3/11095_2017_2174_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f303/5533858/1ee91b9139e6/11095_2017_2174_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f303/5533858/08cc91341d76/11095_2017_2174_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f303/5533858/4dbdf511a870/11095_2017_2174_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f303/5533858/30fff98cabb5/11095_2017_2174_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f303/5533858/86c22b1c39fd/11095_2017_2174_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f303/5533858/b4fcdfa59d2d/11095_2017_2174_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f303/5533858/77040df1e6e3/11095_2017_2174_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f303/5533858/1ee91b9139e6/11095_2017_2174_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f303/5533858/08cc91341d76/11095_2017_2174_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f303/5533858/4dbdf511a870/11095_2017_2174_Fig7_HTML.jpg

相似文献

1
The Need for Restructuring the Disordered Science of Amorphous Drug Formulations.重组无序的无定形药物制剂科学的必要性。
Pharm Res. 2017 Sep;34(9):1754-1772. doi: 10.1007/s11095-017-2174-7. Epub 2017 May 18.
2
Co amorphous systems: A product development perspective.共无定形系统:产品开发视角。
Int J Pharm. 2016 Dec 30;515(1-2):403-415. doi: 10.1016/j.ijpharm.2016.10.043. Epub 2016 Oct 19.
3
Support Tools in Formulation Development for Poorly Soluble Drugs.难溶性药物制剂开发中的支持工具
J Pharm Sci. 2016 Aug;105(8):2260-9. doi: 10.1016/j.xphs.2016.05.024. Epub 2016 Jun 29.
4
Barrier coated drug layered particles for enhanced performance of amorphous solid dispersion dosage form.包衣药物层颗粒提高无定形固体分散体剂型的性能。
J Pharm Sci. 2012 Jan;101(1):342-53. doi: 10.1002/jps.22743. Epub 2011 Sep 20.
5
Influence of Glass Forming Ability on the Physical Stability of Supersaturated Amorphous Solid Dispersions.玻璃化形成能力对过饱和无定形固体分散体物理稳定性的影响。
J Pharm Sci. 2019 Aug;108(8):2561-2569. doi: 10.1016/j.xphs.2019.02.028. Epub 2019 Mar 13.
6
Computational prediction of formulation strategies for beyond-rule-of-5 compounds.基于规则 5 以外化合物的制剂策略的计算预测。
Adv Drug Deliv Rev. 2016 Jun 1;101:6-21. doi: 10.1016/j.addr.2016.02.005. Epub 2016 Feb 27.
7
Polymeric Amorphous Solid Dispersions: A Review of Amorphization, Crystallization, Stabilization, Solid-State Characterization, and Aqueous Solubilization of Biopharmaceutical Classification System Class II Drugs.聚合物无定形固体分散体:生物药剂学分类系统II类药物的非晶化、结晶、稳定化、固态表征及水相增溶综述
J Pharm Sci. 2016 Sep;105(9):2527-2544. doi: 10.1016/j.xphs.2015.10.008. Epub 2016 Jan 23.
8
Drug-polymer solubility and miscibility: Stability consideration and practical challenges in amorphous solid dispersion development.药物-聚合物的溶解度和混溶性:无定形固体分散体开发中的稳定性考虑和实际挑战。
J Pharm Sci. 2010 Jul;99(7):2941-7. doi: 10.1002/jps.22074.
9
Molecular Dynamics, Recrystallization Behavior, and Water Solubility of the Amorphous Anticancer Agent Bicalutamide and Its Polyvinylpyrrolidone Mixtures.非晶态抗癌药物比卡鲁胺及其聚乙烯吡咯烷酮混合物的分子动力学、再结晶行为和水溶性
Mol Pharm. 2017 Apr 3;14(4):1071-1081. doi: 10.1021/acs.molpharmaceut.6b01007. Epub 2017 Mar 7.
10
Recent Advances in Understanding the Micro- and Nanoscale Phenomena of Amorphous Solid Dispersions.理解无定形固体分散体的微观和纳米现象的最新进展。
Mol Pharm. 2019 Oct 7;16(10):4089-4103. doi: 10.1021/acs.molpharmaceut.9b00601. Epub 2019 Sep 5.

引用本文的文献

1
Two-Step Nucleation and Amorphization of Carbamazepine Using a Micro-Droplet Precipitation System.使用微滴沉淀系统实现卡马西平的两步成核与非晶化
Pharmaceutics. 2025 Aug 9;17(8):1035. doi: 10.3390/pharmaceutics17081035.
2
Composites of N-butyl-N-methyl-1-phenylpyrrolo[1,2-a]pyrazine-3-carboxamide with Polymers: Effect of Crystallinity on Solubility and Stability.N-正丁基-N-甲基-1-苯基吡咯并[1,2-a]吡嗪-3-甲酰胺与聚合物的复合材料:结晶度对溶解度和稳定性的影响。
Int J Mol Sci. 2023 Jul 30;24(15):12215. doi: 10.3390/ijms241512215.
3
New Development in Understanding Drug-Polymer Interactions in Pharmaceutical Amorphous Solid Dispersions from Solid-State Nuclear Magnetic Resonance.

本文引用的文献

1
Mechanism-based selection of stabilization strategy for amorphous formulations: Insights into crystallization pathways.基于机制的无定形制剂稳定化策略选择:对结晶途径的见解
J Control Release. 2017 Jun 28;256:193-202. doi: 10.1016/j.jconrel.2017.04.015. Epub 2017 Apr 12.
2
Amorphous nanoparticle complex of perphenazine and dextran sulfate as a new solubility enhancement strategy of antipsychotic perphenazine.奋乃静与硫酸葡聚糖的无定形纳米颗粒复合物作为抗精神病药物奋乃静的一种新的溶解度增强策略。
Drug Dev Ind Pharm. 2017 Jun;43(6):996-1002. doi: 10.1080/03639045.2017.1287721. Epub 2017 Feb 13.
3
Orodispersible films based on amorphous solid dispersions of tetrabenazine.
从固态核磁共振看药物-聚合物相互作用在药物无定形固体分散体中的新发展。
Mol Pharm. 2022 Nov 7;19(11):3685-3699. doi: 10.1021/acs.molpharmaceut.2c00479. Epub 2022 Aug 29.
4
Investigating In Vitro and Ex Vivo Properties of Artemether/Lumefantrine Double-Fixed Dose Combination Lipid Matrix Tablets Prepared by Hot Fusion.考察热熔法制备的蒿甲醚/本芴醇双固定剂量复方脂质基质片的体外和离体性质。
Pharmaceutics. 2021 Jun 22;13(7):922. doi: 10.3390/pharmaceutics13070922.
5
Low Molecular Weight Oligomers of Poly(alkylene succinate) Polyesters as Plasticizers in Poly(vinyl alcohol) Based Pharmaceutical Applications.聚(亚烷基琥珀酸酯)聚酯的低分子量低聚物作为增塑剂在基于聚乙烯醇的药物应用中的研究
Polymers (Basel). 2021 Jan 1;13(1):146. doi: 10.3390/polym13010146.
6
Critical Excipient Properties for the Dissolution Enhancement of Phenytoin.增强苯妥英钠溶出度的关键辅料特性
ACS Omega. 2019 Nov 6;4(21):19116-19127. doi: 10.1021/acsomega.9b02383. eCollection 2019 Nov 19.
7
Long-Term Physical (In)Stability of Spray-Dried Amorphous Drugs: Relationship with Glass-Forming Ability and Physicochemical Properties.喷雾干燥无定形药物的长期物理(不)稳定性:与玻璃形成能力和物理化学性质的关系
Pharmaceutics. 2019 Aug 21;11(9):425. doi: 10.3390/pharmaceutics11090425.
8
Analytical and Computational Methods for the Estimation of Drug-Polymer Solubility and Miscibility in Solid Dispersions Development.固体分散体开发中药物-聚合物溶解度和混溶性估算的分析与计算方法
Pharmaceutics. 2019 Aug 1;11(8):372. doi: 10.3390/pharmaceutics11080372.
9
Supersaturation Potential of Amorphous Active Pharmaceutical Ingredients after Long-Term Storage.无定形原料药长期储存后的过饱和度潜力。
Molecules. 2019 Jul 27;24(15):2731. doi: 10.3390/molecules24152731.
10
Amorphisation of Free Acid Ibuprofen and Other Profens in Mixtures with Nanocellulose: Dry Powder Formulation Strategy for Enhanced Solubility.游离酸布洛芬及其他洛芬与纳米纤维素混合物的非晶化:提高溶解度的干粉制剂策略
Pharmaceutics. 2019 Feb 6;11(2):68. doi: 10.3390/pharmaceutics11020068.
基于四苯嗪无定形固体分散体的口崩片。
Int J Pharm. 2017 Feb 25;518(1-2):242-252. doi: 10.1016/j.ijpharm.2016.12.036. Epub 2016 Dec 19.
4
Molecular Dynamics Simulation of Amorphous Hydroxypropylmethylcellulose and Its Mixtures With Felodipine and Water.羟丙基甲基纤维素无定形体及其与非洛地平、水混合物的分子动力学模拟
J Pharm Sci. 2017 Mar;106(3):803-816. doi: 10.1016/j.xphs.2016.10.026. Epub 2016 Dec 13.
5
Design of PVP/VA S-630 based tadalafil solid dispersion to enhance the dissolution rate.基于PVP/VA S-630的他达拉非固体分散体设计以提高溶出速率。
Eur J Pharm Sci. 2017 Jan 15;97:269-276. doi: 10.1016/j.ejps.2016.11.030. Epub 2016 Dec 2.
6
Glass-forming ability of compounds in marketed amorphous drug products.市售无定形药物产品中化合物的玻璃形成能力。
Eur J Pharm Biopharm. 2017 Mar;112:204-208. doi: 10.1016/j.ejpb.2016.11.031. Epub 2016 Nov 27.
7
Experimental observations and dissipative particle dynamic simulations on microstructures of pH-sensitive polymer containing amorphous solid dispersions.含无定形固体分散体的pH敏感聚合物微观结构的实验观察与耗散粒子动力学模拟
Int J Pharm. 2017 Jan 30;517(1-2):185-195. doi: 10.1016/j.ijpharm.2016.11.049. Epub 2016 Nov 25.
8
Oral hesperidin-Amorphization and improved dissolution properties by controlled loading onto porous silica.口服橙皮苷无定形化及其通过控制负载到多孔硅石上改善溶解性能。
Int J Pharm. 2017 Feb 25;518(1-2):253-263. doi: 10.1016/j.ijpharm.2016.11.005. Epub 2016 Nov 18.
9
Pharmaceutical Amorphous Nanoparticles.药物非晶态纳米颗粒
J Pharm Sci. 2017 Jan;106(1):39-65. doi: 10.1016/j.xphs.2016.09.014. Epub 2016 Nov 2.
10
High-Throughput Excipient Discovery Enables Oral Delivery of Poorly Soluble Pharmaceuticals.高通量辅料发现助力难溶性药物的口服给药。
ACS Cent Sci. 2016 Oct 26;2(10):748-755. doi: 10.1021/acscentsci.6b00268. Epub 2016 Oct 12.